Journal Information
Vol. 17. Issue 3.
Pages 387 (May - June 2013)
Share
Share
Download PDF
More article options
Vol. 17. Issue 3.
Pages 387 (May - June 2013)
Erratum
Open Access
Erratum in «High rate of virologic supression with darunavir/ritonavir plus optimazed background therapy among highly antiretroviral-experienced HIV-infected patients: results of a prospective cohort study in São Paulo, Brazil»
Visits
3325
José Ernesto Vidala,b,
Corresponding author
josevibe@gmail.com

Corresponding author: Department of Infectious Diseases, Instituto de Infectologia Emílio Ribas, Avenida Doutor Arnaldo, Cerqueira, César, São Paulo, SP, 01246-000, Brazil. Tel.: +55 11 38961200; fax: +55 11 38961200.
, Alice Tung Wan Songa, Maria Laura Matosa, Daniel Bartmanna, Guilherme dos Anjosa, Érique José Peixoto de Mirandaa, Ângela Carvalho Freitasa, Mirian de Freitas Dalbena, Claudinei Santanac, Aluísio Cotrim Seguradoa, Cláudia Cortese Barretod,e, Adrián Vladimir Hernándezf
a Department of Infectious Diseases, Medical School, Universidade de São Paulo, São Paulo, SP, Brazil
b Department of Infectious Diseases, Instituto de Infectologia Emílio Ribas, São Paulo, SP, Brazil
c Pharmacy School, Universidade de São Paulo, São Paulo, SP, Brazil
d Pro-Blood Foundation/Blood Center of São Paulo (FPS/HSP), Medical School, Universidade de São Paulo, São Paulo, SP, Brazil
e Laboratory of Medical Investigation in Dermatology and Immunodeficiencies – LIM-56, Department of Dermatology, Medical School, Universidade de São Paulo, São Paulo, SP, Brazil
f Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, USA
Related content
José Ernesto Vidal, Alice Tung Wan Song, Maria Laura Matos, Daniel Bartmann, Guilherme dos Anjos, Érique José Peixoto de Miranda, Ângela Carvalho Freitas, Mirian de Freitas Dalben, Claudinei Santana, Aluísio Cotrim Segurado, Cláudia Cortese Barreto, Adrián Vladimir Hernández
This item has received

Under a Creative Commons license
Article information
Full Text

In the article “High rate of virologic supression with darunavir/ritonavir plus optimazed background therapy among highly antiretroviral-experienced HIV-infected patients: results of a prospective cohort study in São Paulo, Brazil”, published in Braz J Infect Dis. 2013 Feb;17(1):41-7, please consider the following corrections:

Page 43, Table 1, line 18, “Previous use of NRTI, NNRTI and PIs: 87 (95)” should read as “Previous use of NRTI, NNRTI and PIs: 92 (100%)”.

Page 43, Results section, lines 28-31, “Tenofovir was the most frequent NRTI used (n=83, 90.2%) and its genotyping evaluation were: sensitive: 16 (17.4%), intermediate resistance: 8 (8.7%), and resistance: 68 (73.9%).” should read as “All patients received lamivudine and their genotyping evaluation were resistant in all cases. Tenofovir was the second most frequent NRTI used (n=83, 90.2%) and its genotyping evaluation were: sensitive:14 (16.9%), intermediate resistance: 7 (8.4%), and resistance: 62 (74.7%).”

DOI of the original article: http://dx.doi.org/10.1016/j.bjid.2012.08.022

The Brazilian Journal of Infectious Diseases
Article options
Tools